Lingohr Asset Management GmbH purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,170 shares of the company's stock, valued at approximately $357,000.
Several other institutional investors have also added to or reduced their stakes in BNTX. FMR LLC raised its stake in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after acquiring an additional 5,598,190 shares during the last quarter. Flossbach Von Storch SE grew its position in shares of BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after buying an additional 47,236 shares during the last quarter. Fred Alger Management LLC purchased a new position in shares of BioNTech during the third quarter valued at approximately $59,485,000. abrdn plc raised its holdings in shares of BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after acquiring an additional 159,676 shares in the last quarter. Finally, LBP AM SA lifted its stake in BioNTech by 2.1% in the fourth quarter. LBP AM SA now owns 252,918 shares of the company's stock worth $28,820,000 after acquiring an additional 5,085 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.
BioNTech Stock Up 5.5 %
NASDAQ BNTX traded up $5.26 during mid-day trading on Monday, reaching $100.64. The stock had a trading volume of 982,469 shares, compared to its average volume of 784,436. The stock has a market cap of $24.15 billion, a PE ratio of -47.92 and a beta of 0.30. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a fifty day moving average price of $112.76 and a 200 day moving average price of $113.79.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter in the previous year, the business earned $1.90 earnings per share. The company's revenue was down 19.5% on a year-over-year basis. On average, research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have commented on BNTX. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price objective for the company. BMO Capital Markets increased their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Morgan Stanley cut their price objective on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. JPMorgan Chase & Co. reduced their target price on BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a report on Tuesday, November 26th. Finally, Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 target price for the company. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $143.73.
Check Out Our Latest Stock Analysis on BioNTech
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Recommended Stories
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
